Clinical Trials Browser

Phase 2 × Active not recruiting × sintilimab × Clear all

NCT07005336 2026-01-30

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05177068 2025-10-02

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT05481476 2025-09-04

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03869034 2024-12-03

HAICPD1-HCC

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06667050 2024-10-31

CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Gastric Adenocarcinoma

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Phase 2 Active not recruiting

Lung Neoplasms

NCT04718415 2024-09-19

OOC-001

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05244213 2024-07-08

NEOTIDE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04326153 2024-02-01

Neo-Pre-IC

Phase 2 Active not recruiting

IIIA Stage Non-small Cell Lung Cancer

NCT04304209 2023-02-01

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms